REGNÂ – Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.REGN
$771.87Name : Regeneron Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $81,808,523,264.00
EPSttm : 41.76
Regeneron Pharmaceuticals, Inc.
$771.87
0.27%$2.07Float Short %
2.71
Margin Of Safety %
-8
Put/Call OI Ratio
0.5
EPS Next Q Diff
-1.35
EPS Last/This Y
2.28
EPS This/Next Y
-4.45
Price
771.86
Target Price
802.96
Analyst Recom
1.83
Performance Q
28.66
Relative Volume
0.34
Beta
0.39
Ticker: REGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-02 | REGN | 741.55 | 0.46 | 1.27 | 54832 |
| 2025-12-03 | REGN | 722.27 | 0.47 | 0.78 | 55969 |
| 2025-12-04 | REGN | 722.79 | 0.48 | 2.32 | 57142 |
| 2025-12-05 | REGN | 718.26 | 0.48 | 1.40 | 57400 |
| 2025-12-08 | REGN | 703.1 | 0.48 | 1.46 | 56884 |
| 2025-12-09 | REGN | 692.23 | 0.48 | 1.19 | 57248 |
| 2025-12-10 | REGN | 726.38 | 0.48 | 0.41 | 57664 |
| 2025-12-11 | REGN | 747.4 | 0.48 | 0.58 | 58468 |
| 2025-12-12 | REGN | 741.49 | 0.48 | 1.88 | 58962 |
| 2025-12-15 | REGN | 752.72 | 0.49 | 1.94 | 57623 |
| 2025-12-16 | REGN | 746.44 | 0.49 | 0.93 | 58003 |
| 2025-12-17 | REGN | 750.01 | 0.50 | 0.71 | 58262 |
| 2025-12-18 | REGN | 748.74 | 0.50 | 3.51 | 58636 |
| 2025-12-19 | REGN | 767.76 | 0.51 | 0.44 | 59377 |
| 2025-12-22 | REGN | 780.36 | 0.47 | 1.04 | 49077 |
| 2025-12-23 | REGN | 786.17 | 0.47 | 0.84 | 50094 |
| 2025-12-26 | REGN | 784.33 | 0.48 | 1.21 | 51250 |
| 2025-12-29 | REGN | 780.59 | 0.49 | 0.83 | 50546 |
| 2025-12-30 | REGN | 774.73 | 0.49 | 1.31 | 51195 |
| 2025-12-31 | REGN | 772.15 | 0.50 | 1.70 | 51596 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-02 | REGN | 742.00 | -10.9 | -1408.6 | 43.22 |
| 2025-12-03 | REGN | 723.67 | -10.9 | -1465.9 | 43.22 |
| 2025-12-04 | REGN | 722.91 | -10.9 | -1368.4 | 43.22 |
| 2025-12-05 | REGN | 718.36 | -10.9 | -1389.4 | 43.22 |
| 2025-12-08 | REGN | 703.26 | -10.9 | - | 43.22 |
| 2025-12-09 | REGN | 692.58 | -10.8 | -1379.0 | 43.23 |
| 2025-12-10 | REGN | 726.27 | -10.8 | -1110.8 | 43.23 |
| 2025-12-11 | REGN | 746.92 | -10.8 | -1195.9 | 43.23 |
| 2025-12-12 | REGN | 741.31 | -10.8 | -1351.1 | 43.23 |
| 2025-12-15 | REGN | 752.62 | -10.8 | -1256.6 | 43.23 |
| 2025-12-16 | REGN | 752.62 | -11.3 | -1355.3 | 43.18 |
| 2025-12-17 | REGN | 750.08 | -11.3 | -1299.7 | 43.18 |
| 2025-12-18 | REGN | 748.55 | -11.3 | -1327.4 | 43.18 |
| 2025-12-19 | REGN | 767.76 | -11.3 | -1214.3 | 43.18 |
| 2025-12-22 | REGN | 778.49 | -11.3 | -1262.1 | 43.18 |
| 2025-12-23 | REGN | 785.52 | -11.3 | -1293.3 | 43.18 |
| 2025-12-26 | REGN | 784.19 | -11.3 | -1317.9 | 43.18 |
| 2025-12-29 | REGN | 780.72 | -11.3 | -1343.0 | 43.18 |
| 2025-12-30 | REGN | 774.62 | -11.3 | -1351.8 | 43.18 |
| 2025-12-31 | REGN | 771.86 | -11.3 | -1331.7 | 43.18 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-02 | REGN | -0.20 | -0.88 | 2.81 |
| 2025-12-03 | REGN | -0.20 | -0.88 | 2.81 |
| 2025-12-04 | REGN | -0.20 | -0.88 | 2.81 |
| 2025-12-05 | REGN | -0.20 | -0.88 | 2.81 |
| 2025-12-08 | REGN | -0.20 | -0.98 | 2.81 |
| 2025-12-09 | REGN | -0.20 | -0.98 | 2.81 |
| 2025-12-10 | REGN | -0.20 | -0.98 | 3.11 |
| 2025-12-11 | REGN | -0.20 | -0.98 | 3.11 |
| 2025-12-12 | REGN | -0.20 | -0.98 | 3.11 |
| 2025-12-15 | REGN | -0.20 | -0.94 | 3.11 |
| 2025-12-16 | REGN | -0.20 | -0.94 | 3.11 |
| 2025-12-17 | REGN | -0.19 | -0.94 | 3.11 |
| 2025-12-18 | REGN | -0.19 | -0.94 | 3.11 |
| 2025-12-19 | REGN | -0.19 | -0.94 | 3.11 |
| 2025-12-22 | REGN | -0.19 | -1.01 | 3.11 |
| 2025-12-23 | REGN | -0.19 | -1.01 | 3.11 |
| 2025-12-26 | REGN | -0.19 | -1.01 | 2.71 |
| 2025-12-29 | REGN | -0.19 | -1.01 | 2.71 |
| 2025-12-30 | REGN | -0.19 | -1.01 | 2.71 |
| 2025-12-31 | REGN | -0.19 | -1.01 | 2.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
11.83
Avg. EPS Est. Current Quarter
10.71
Avg. EPS Est. Next Quarter
10.48
Insider Transactions
-0.19
Institutional Transactions
-1.01
Beta
0.39
Average Sales Estimate Current Quarter
3758
Average Sales Estimate Next Quarter
3435
Fair Value
712.21
Quality Score
99
Growth Score
75
Sentiment Score
21
Actual DrawDown %
36.3
Max Drawdown 5-Year %
-59.7
Target Price
802.96
P/E
18.48
Forward P/E
17.39
PEG
3.46
P/S
5.69
P/B
2.63
P/Free Cash Flow
19.22
EPS
41.77
Average EPS Est. Cur. Y​
43.18
EPS Next Y. (Est.)
38.73
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
32.13
Relative Volume
0.34
Return on Equity vs Sector %
-12.5
Return on Equity vs Industry %
2.9
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
-1331.7
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15222
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies; and Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading